Last reviewed: June 24, 2026

Last updated: June 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Type 1 diabetes management has expanded beyond insulin alone, with some endocrinologists prescribing GLP-1 receptor agonists like semaglutide off-label to support blood sugar regulation and address weight gain concerns. While not FDA-approved specifically for Type 1 diabetes, emerging clinical experience and small studies suggest potential metabolic benefits when combined with insulin therapy under close medical supervision.

Understanding GLP-1 Receptor Agonists in Type 1 Diabetes

GLP-1 receptor agonists work by stimulating the pancreas to release insulin in response to meals and by slowing gastric emptying, which stabilizes blood glucose levels. In Type 1 diabetes, where the immune system damages insulin-producing beta cells, semaglutide does not replace insulin but rather enhances the body's ability to use it more efficiently. This mechanism differs fundamentally from Type 2 diabetes treatment, where the medication addresses insulin resistance and insufficient insulin secretion.

Clinical interest in semaglutide for Type 1 diabetes has grown because many patients experience weight gain from insulin therapy and struggle with postprandial (after-meal) blood sugar spikes. Small observational studies and case reports have documented modest improvements in HbA1c levels and reduced insulin requirements in some Type 1 patients, though large randomized controlled trials specific to this population remain limited. The decision to use semaglutide in Type 1 diabetes is highly individualized and requires partnership with an endocrinologist experienced in both insulin management and GLP-1 therapy.

Off-Label Use and Clinical Evidence for Type 1 Diabetes

Off-label prescribing is a standard medical practice in which physicians use FDA-approved medications for conditions or patient populations beyond their labeled indication. Semaglutide is FDA-approved for Type 2 diabetes and chronic weight management in adults, but not for Type 1 diabetes; however, physicians may prescribe it off-label based on clinical judgment and emerging evidence. Several small studies and case series have shown that Type 1 patients using semaglutide alongside insulin achieved reductions in HbA1c of 0.5% to 1.5% and experienced decreased insulin needs, though these findings require validation in larger trials.

The proposed mechanism in Type 1 diabetes involves semaglutide's ability to slow gastric emptying, suppress glucagon inappropriately released by dysfunctional alpha cells, and potentially reduce overall caloric intake through appetite suppression. Patients should understand that off-label use carries inherent risks and requires rigorous glucose monitoring, regular clinic visits, and open communication with their diabetes care team. PlexusDx supports patients working with their physicians on off-label treatments by providing affordable, consistently dosed compounded semaglutide from licensed 503A pharmacies.

Safety Considerations and Hypoglycemia Risk in Type 1 Diabetes

The most significant safety concern when adding semaglutide to Type 1 diabetes treatment is the increased risk of hypoglycemia, particularly if insulin doses are not appropriately reduced. Because semaglutide enhances insulin secretion (via remaining beta cell function) and delays gastric emptying, the combination can lower blood glucose more aggressively than insulin alone, requiring careful dose titration and frequent self-monitoring of blood glucose (SMBG). Patients using continuous glucose monitors (CGMs) have a significant advantage in tracking real-time glucose trends and detecting low glucose episodes early.

Other potential side effects common to GLP-1 therapy include nausea, vomiting, diarrhea, and gastroparesis-like symptoms, which may be more pronounced in Type 1 patients already managing multiple medications. Diabetic ketoacidosis (DKA) is a rare but serious concern documented in case reports of GLP-1 use in Type 1 diabetes, particularly during periods of reduced food intake, illness, or insulin omission. Any patient considering semaglutide for Type 1 diabetes must receive thorough education on warning signs of DKA, hypoglycemia, and the absolute necessity of maintaining insulin therapy while gradually titrating semaglutide under physician supervision.

Accessing Compounded Semaglutide Through PlexusDx

PlexusDx compounded semaglutide injections begin at $149 per month and are prepared by licensed 503A compounding pharmacies that meet rigorous pharmaceutical standards. The service requires no insurance and no membership fee, making it accessible to Type 1 patients seeking an alternative to brand-name Ozempic or those facing coverage denials for off-label use. PlexusDx serves all 50 states and allows patients to use HSA or FSA accounts to pay for treatment, reducing out-of-pocket costs.

Patients can work with their own endocrinologist or utilize telehealth partners within the PlexusDx network to obtain a prescription for compounded semaglutide. Once prescribed, the medication is shipped directly to the patient's home with detailed instructions for injection technique and dose escalation. For those interested in understanding their genetic predisposition to GLP-1 responsiveness, the Precision Peptide Genetic Test ($99 add-on after the first month) analyzes variants in GLP1R, GIPR, FTO, and MC4R genes to inform personalized treatment optimization.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide FDA-approved for Type 1 diabetes?

No, semaglutide is not FDA-approved for Type 1 diabetes; it is approved for Type 2 diabetes and chronic weight management. However, physicians may prescribe it off-label for Type 1 patients based on clinical judgment. This decision should always involve discussion with an endocrinologist experienced in both insulin management and GLP-1 therapy.

What clinical evidence supports semaglutide use in Type 1 diabetes?

Evidence is limited to small observational studies and case reports showing modest HbA1c reductions (0.5–1.5%) and decreased insulin requirements in some Type 1 patients. Large randomized controlled trials specific to Type 1 diabetes are needed. Current use is based on individual patient factors and close medical supervision rather than robust trial data.

How much does compounded semaglutide cost at PlexusDx?

PlexusDx compounded semaglutide injections start at $149 per month with no insurance required and no membership fee. The flat monthly price remains the same regardless of your dose—your dose may need to go up, but your price won't. All medications come from licensed 503A compounding pharmacies.

What is the main safety risk of semaglutide in Type 1 diabetes?

Hypoglycemia is the primary safety concern because semaglutide enhances insulin action and slows gastric emptying, both of which can lower blood glucose. Insulin doses must be reduced and carefully monitored, and patients should use continuous glucose monitors when possible. Rare cases of diabetic ketoacidosis have been reported, making careful oversight by an endocrinologist essential.

What does the PlexusDx Precision Peptide Genetic Test measure?

The Precision Peptide Genetic Test ($99 add-on after month one) analyzes your DNA across 14 metabolic pathways, 49 peptides, and 150+ genetic insights to identify variants in GLP1R, GIPR, FTO, and MC4R that influence how your body responds to GLP-1 therapy. This personalized data helps optimize your treatment plan in partnership with your physician.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves